PHM-Exch> Public Eye calls on the Swiss Federal Council to use compulsory license on Roche's breast cancer

[Claudio Schuftan]

From: Susana Barria <sbarria at phmovement.org>

On Tue 12 Feb, 2019, 19:57 Alexandre G. <alexandre_gajardo at hotmail.com
wrote:

>
> Public Eye, a Swiss NGO, formally asked the Swiss government to issue a
> compulsory license on Perjeta (pertuzumab), a Roche's breast cancer drug.
>
> For this purpose, Public Eye prepared a model of request, that you can
> find here
> <https://www.publiceye.ch/fileadmin/doc/Medikamente/PublicEye_CL-Request-Perjeta_CH_2019.pdf>
> (in english).
>
> Press release in french here
> <https://www.publiceye.ch/fr/coin-medias/communiques-de-presse/detail/demande-licence-obligatoire-prete-a-lemploi>
> .
>
> The objectives of this action are to put pressure on the Swiss government,
> in order to address the lack of transparency in drug pricing and cost of
> R&D, but also to question the swiss position regarding the use of TRIPs
> flexibilities. Indeed, in the past, Switzerland, alonside with the EU and
> the US, put a lot of pressure on Middle Income Countries, such as Thailand
> and Colombia, to prevent them from using TRIPs flexibilities, especially
> compulsory licenses.
>
>
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://phm.phmovement.org/pipermail/phm-exchange-phmovement.org/attachments/20190213/90a4d459/attachment.html>